Top Markets
Coin of the day
Grace Therapeutics, Inc. Grace Therapeutics, Inc.

Grace Therapeutics, Inc.

GRCE
Rank in Stocks #27036
Grace Therapeutics, Inc. specializes in the creation and commercialization of... Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Share Price
$2.18
Last synced: 2026-08-19
Market Cap
$35.55M
Change (1 day)
2.57%
Change (1 year)
-33.19%
Country
US
Trade Grace Therapeutics, Inc. (GRCE)

Category

P/B ratio for Grace Therapeutics, Inc. (GRCE)
P/B ratio as of 2026 TTM: 0
According to Grace Therapeutics, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Grace Therapeutics, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
3.7087 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH